TrialDiabetes, obesity & metabolism2022

Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.

Charlotte C van Ruiten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.